GTPase activity plays a key role in the pathobiology of LRRK2

Yulan Xiong, Candice E. Coombes, Austin Kilaru, Xiaojie Li, Aaron D. Gitler, William J. Bowers, Valina Dawson, Ted M Dawson, Darren J. Moore

Research output: Contribution to journalArticle

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are associated with late-onset, autosomal-dominant, familial Parkinson's disease (PD) and also contribute to sporadic disease. The LRRK2 gene encodes a large protein with multiple domains, including functional Roc GTPase and protein kinase domains. Mutations in LRRK2 most likely cause disease through a toxic gain-of-function mechanism. The expression of human LRRK2 variants in cultured primary neurons induces toxicity that is dependent on intact GTP binding or kinase activities. However, the mechanism(s) underlying LRRK2-induced neuronal toxicity is poorly understood, and the contribution of GTPase and/or kinase activity to LRRK2 pathobiology is not well defined. To explore the pathobiology of LRRK2, we have developed a model of LRRK2 cytotoxicity in the baker's yeast Saccharomyces cerevisiae. Protein domain analysis in this model reveals that expression of GTPase domain-containing fragments of human LRRK2 are toxic. LRRK2 toxicity in yeast can be modulated by altering GTPase activity and is closely associated with defects in endocytic vesicular trafficking and autophagy. These truncated LRRK2 variants induce similar toxicity in both yeast and primary neuronal models and cause similar vesicular defects in yeast as full-length LRRK2 causes in primary neurons. The toxicity induced by truncated LRRK2 variants in yeast acts through a mechanism distinct from toxicity induced by human a-synuclein. A genome-wide genetic screen identified modifiers of LRRK2-induced toxicity in yeast including components of vesicular trafficking pathways, which can also modulate the trafficking defects caused by expression of truncated LRRK2 variants. Our results provide insight into the basic pathobiology of LRRK2 and suggest that the GTPase domain may contribute to the toxicity of LRRK2. These findings may guide future therapeutic strategies aimed at attenuating LRRK2-mediated neurodegeneration.

Original languageEnglish (US)
JournalPLoS Genetics
Volume6
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

GTP Phosphohydrolases
guanosinetriphosphatase
Leucine
leucine
phosphotransferases (kinases)
Phosphotransferases
toxicity
yeast
trafficking
defect
protein
mutation
Yeasts
yeasts
gene
Poisons
Saccharomyces cerevisiae
genome
Synucleins
neurons

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Ecology, Evolution, Behavior and Systematics
  • Cancer Research
  • Genetics(clinical)

Cite this

Xiong, Y., Coombes, C. E., Kilaru, A., Li, X., Gitler, A. D., Bowers, W. J., ... Moore, D. J. (2010). GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genetics, 6(4). https://doi.org/10.1371/journal.pgen.1000902

GTPase activity plays a key role in the pathobiology of LRRK2. / Xiong, Yulan; Coombes, Candice E.; Kilaru, Austin; Li, Xiaojie; Gitler, Aaron D.; Bowers, William J.; Dawson, Valina; Dawson, Ted M; Moore, Darren J.

In: PLoS Genetics, Vol. 6, No. 4, 04.2010.

Research output: Contribution to journalArticle

Xiong, Y, Coombes, CE, Kilaru, A, Li, X, Gitler, AD, Bowers, WJ, Dawson, V, Dawson, TM & Moore, DJ 2010, 'GTPase activity plays a key role in the pathobiology of LRRK2', PLoS Genetics, vol. 6, no. 4. https://doi.org/10.1371/journal.pgen.1000902
Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, Bowers WJ et al. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genetics. 2010 Apr;6(4). https://doi.org/10.1371/journal.pgen.1000902
Xiong, Yulan ; Coombes, Candice E. ; Kilaru, Austin ; Li, Xiaojie ; Gitler, Aaron D. ; Bowers, William J. ; Dawson, Valina ; Dawson, Ted M ; Moore, Darren J. / GTPase activity plays a key role in the pathobiology of LRRK2. In: PLoS Genetics. 2010 ; Vol. 6, No. 4.
@article{4f19dade8e6e4c76b61c137a01908d7a,
title = "GTPase activity plays a key role in the pathobiology of LRRK2",
abstract = "Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are associated with late-onset, autosomal-dominant, familial Parkinson's disease (PD) and also contribute to sporadic disease. The LRRK2 gene encodes a large protein with multiple domains, including functional Roc GTPase and protein kinase domains. Mutations in LRRK2 most likely cause disease through a toxic gain-of-function mechanism. The expression of human LRRK2 variants in cultured primary neurons induces toxicity that is dependent on intact GTP binding or kinase activities. However, the mechanism(s) underlying LRRK2-induced neuronal toxicity is poorly understood, and the contribution of GTPase and/or kinase activity to LRRK2 pathobiology is not well defined. To explore the pathobiology of LRRK2, we have developed a model of LRRK2 cytotoxicity in the baker's yeast Saccharomyces cerevisiae. Protein domain analysis in this model reveals that expression of GTPase domain-containing fragments of human LRRK2 are toxic. LRRK2 toxicity in yeast can be modulated by altering GTPase activity and is closely associated with defects in endocytic vesicular trafficking and autophagy. These truncated LRRK2 variants induce similar toxicity in both yeast and primary neuronal models and cause similar vesicular defects in yeast as full-length LRRK2 causes in primary neurons. The toxicity induced by truncated LRRK2 variants in yeast acts through a mechanism distinct from toxicity induced by human a-synuclein. A genome-wide genetic screen identified modifiers of LRRK2-induced toxicity in yeast including components of vesicular trafficking pathways, which can also modulate the trafficking defects caused by expression of truncated LRRK2 variants. Our results provide insight into the basic pathobiology of LRRK2 and suggest that the GTPase domain may contribute to the toxicity of LRRK2. These findings may guide future therapeutic strategies aimed at attenuating LRRK2-mediated neurodegeneration.",
author = "Yulan Xiong and Coombes, {Candice E.} and Austin Kilaru and Xiaojie Li and Gitler, {Aaron D.} and Bowers, {William J.} and Valina Dawson and Dawson, {Ted M} and Moore, {Darren J.}",
year = "2010",
month = "4",
doi = "10.1371/journal.pgen.1000902",
language = "English (US)",
volume = "6",
journal = "PLoS Genetics",
issn = "1553-7390",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - GTPase activity plays a key role in the pathobiology of LRRK2

AU - Xiong, Yulan

AU - Coombes, Candice E.

AU - Kilaru, Austin

AU - Li, Xiaojie

AU - Gitler, Aaron D.

AU - Bowers, William J.

AU - Dawson, Valina

AU - Dawson, Ted M

AU - Moore, Darren J.

PY - 2010/4

Y1 - 2010/4

N2 - Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are associated with late-onset, autosomal-dominant, familial Parkinson's disease (PD) and also contribute to sporadic disease. The LRRK2 gene encodes a large protein with multiple domains, including functional Roc GTPase and protein kinase domains. Mutations in LRRK2 most likely cause disease through a toxic gain-of-function mechanism. The expression of human LRRK2 variants in cultured primary neurons induces toxicity that is dependent on intact GTP binding or kinase activities. However, the mechanism(s) underlying LRRK2-induced neuronal toxicity is poorly understood, and the contribution of GTPase and/or kinase activity to LRRK2 pathobiology is not well defined. To explore the pathobiology of LRRK2, we have developed a model of LRRK2 cytotoxicity in the baker's yeast Saccharomyces cerevisiae. Protein domain analysis in this model reveals that expression of GTPase domain-containing fragments of human LRRK2 are toxic. LRRK2 toxicity in yeast can be modulated by altering GTPase activity and is closely associated with defects in endocytic vesicular trafficking and autophagy. These truncated LRRK2 variants induce similar toxicity in both yeast and primary neuronal models and cause similar vesicular defects in yeast as full-length LRRK2 causes in primary neurons. The toxicity induced by truncated LRRK2 variants in yeast acts through a mechanism distinct from toxicity induced by human a-synuclein. A genome-wide genetic screen identified modifiers of LRRK2-induced toxicity in yeast including components of vesicular trafficking pathways, which can also modulate the trafficking defects caused by expression of truncated LRRK2 variants. Our results provide insight into the basic pathobiology of LRRK2 and suggest that the GTPase domain may contribute to the toxicity of LRRK2. These findings may guide future therapeutic strategies aimed at attenuating LRRK2-mediated neurodegeneration.

AB - Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are associated with late-onset, autosomal-dominant, familial Parkinson's disease (PD) and also contribute to sporadic disease. The LRRK2 gene encodes a large protein with multiple domains, including functional Roc GTPase and protein kinase domains. Mutations in LRRK2 most likely cause disease through a toxic gain-of-function mechanism. The expression of human LRRK2 variants in cultured primary neurons induces toxicity that is dependent on intact GTP binding or kinase activities. However, the mechanism(s) underlying LRRK2-induced neuronal toxicity is poorly understood, and the contribution of GTPase and/or kinase activity to LRRK2 pathobiology is not well defined. To explore the pathobiology of LRRK2, we have developed a model of LRRK2 cytotoxicity in the baker's yeast Saccharomyces cerevisiae. Protein domain analysis in this model reveals that expression of GTPase domain-containing fragments of human LRRK2 are toxic. LRRK2 toxicity in yeast can be modulated by altering GTPase activity and is closely associated with defects in endocytic vesicular trafficking and autophagy. These truncated LRRK2 variants induce similar toxicity in both yeast and primary neuronal models and cause similar vesicular defects in yeast as full-length LRRK2 causes in primary neurons. The toxicity induced by truncated LRRK2 variants in yeast acts through a mechanism distinct from toxicity induced by human a-synuclein. A genome-wide genetic screen identified modifiers of LRRK2-induced toxicity in yeast including components of vesicular trafficking pathways, which can also modulate the trafficking defects caused by expression of truncated LRRK2 variants. Our results provide insight into the basic pathobiology of LRRK2 and suggest that the GTPase domain may contribute to the toxicity of LRRK2. These findings may guide future therapeutic strategies aimed at attenuating LRRK2-mediated neurodegeneration.

UR - http://www.scopus.com/inward/record.url?scp=77952391573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952391573&partnerID=8YFLogxK

U2 - 10.1371/journal.pgen.1000902

DO - 10.1371/journal.pgen.1000902

M3 - Article

C2 - 20386743

AN - SCOPUS:77952391573

VL - 6

JO - PLoS Genetics

JF - PLoS Genetics

SN - 1553-7390

IS - 4

ER -